Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells

Cell Death and Differentiation

Volumn 8, Issue 9, 2001, Pages 943-952

  Kampa, M ^a   Hatzoglou, A ^a   Notas, G ^a   Niniraki, M ^a   Kouroumalis, E ^a   Castanas, E ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast cancer; Nitric oxide; Opioids

Indexed keywords

BETA CASOMORPHINE DERIVATIVE; CALCIUM; DELTA OPIATE RECEPTOR AGONIST; DIPRENORPHINE; ENKEPHALIN DERIVATIVE; ETHYLKETAZOCINE; ISOPROTEIN; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR; OXIDOREDUCTASE;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVITY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; TUMOR; WITHDRAWAL SYNDROME;

BREAST NEOPLASMS; CALCIUM; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLAVIN-ADENINE DINUCLEOTIDE; HUMANS; ISOENZYMES; KINETICS; NARCOTIC ANTAGONISTS; NARCOTICS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0034874425     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400893     Document Type: Article

References (83)

1. Opioid receptor and peptide polymorphisms: Potential implications for addictions
2. Identification of a novel opioid peptide derived from alpha-S1 human casein (alpha-S1 casomorphin, and alpha-S1 casomorphin-amide)
3. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors
4. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: Involvement of cytoskeletal elements
5. Early alterations of actin cytoskeleton in OK cells by opioids
6. Differential properties of mu and delta opiate binding sites studied with highly selective ligands
7. Catalysis by nitric oxide synthase
8. Mammalian nitric oxide synthases
9. Guanylate cyclase and the NO/cGMP signaling pathway
10. The dual personality of NO
11. The multifaceted roles of nitric oxide in cancer
12. Effects of nitric oxide-related agents on opioid regulation of rat testicular steroidogenesis
13. The effect of N-nitro-L-arginine methyl ester on morphine-induced changes in the plasma corticosterone and testosterone levels in mice
14. Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine
15. Effects of acute administration of L-arginine on morphine antinociception and morphine distribution in central and peripheral tissues of mice
16. Nitric oxide and opioid tolerance
17. Effect of chronic administration of morphine, U-50, 488H and [D-Pen2, D-Pen5]enkephalin on the concentration of cGMP in brain regions and spinal cord of the mouse
18. Evidence showing that beta-endorphin regulates cyclic guanosine 3′,5′-monophosphate (cGMP) efflux: Anatomical and functional support for an interaction between opiates and nitric oxide
19. Inhibitory pathways and the inhibition of luteinizing hormone-releasing hormone release by alcohol
20. Beta-Endorphin blocks luteinizing hormone-releasing hormone release by inhibiting the nitricoxidergic pathway controlling its release
21. Opioid-glutamate-nitric oxide connection in the regulation of luteinizing hormone secretion in the rat
22. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: Neurovascular regulation
23. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues
24. Basal nitric oxide limits immune, nervous and cardiovascular excitation: Human endothelia express a mu opiate receptor
25. Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase
26. Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation
27. Role of endothelial nitric oxide synthase in hypoxia-induced pial artery dilation
28. Role of neuronal NO synthase in relationship between NO and opioids in hypoxia-induced pial artery dilation
29. The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices
30. Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance
31. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat
32. Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase
33. Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice
34. Attenuation of withdrawal-induced hyperactivity of locus coeruleus neurones by inhibitors of nitric oxide synthase in morphine-dependent rats
35. Ng-nitro-L-arginine, an NOS inhibitor, reduces tolerance to morphine in the rat locus coeruleus
36. Nitric oxide synthase inhibitors attenuate acute and chronic morphine withdrawal response in the rat locus coeruleus: An in vivo voltammetric study
37. Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal
38. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction
39. Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal
40. Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome
41. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor
42. Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester
43. Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta and kappa opioid receptors in acute and prolonged pain in the rat spinal cord
44. Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord
45. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal
46. Met-enkephalin receptor-mediated increase of membrane fluidity modulates nitric oxide (NO) and cGMP production in rat brain synaptosomes
47. Further evidence that nitric oxide modifies acute and chronic morphine actions in mice
48. Evidence for the involvement of nitric oxide and nitric oxide synthase in the modulation of opioid-induced antinociception and the inhibitory effects of exposure to 60-Hz magnetic fields in the land snail
49. Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test
50. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: Evidence for opposing NO actions on morphine analgesia and tolerance
51. Co-localization of muopioid receptor-like immunoreactivity with substance P-LI, calcitonin gene-related peptide-LI and nitric oxide synthase-LI in vagal and glossopharyngeal afferent neurons of the rat
52. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine
53. Nociceptin inhibits tonic nitric oxide release in the mouse isolated proximal colon
54. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth
55. Antiproliferative and receptor binding properties of alpha- and betacasomorphins in the T47D human breast cancer cell line
56. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors
57. Wine antioxidants as antiproliferative agents in human hormone-dependent tumors
58. Structure of redox enzymes
59. Effect of opioid receptor, agonists on nitric oxide synthase activity in rat cerebral cortex homogenate
60. Intravenous beta-endorphin administration fails to alter hypothalamic blood flow in rats expressing normal or reduced nitric oxide synthase activity
61. Opioids inhibit the induction of nitric oxide synthase in J774 macrophages
62. Augmenting effect of opioids on nitrite production by stimulated murine macrophages
63. Chronic morphine exposure and the expression of heme oxygenase type 2
64. Heroin modulates the expression of inducible nitric oxide synthase
65. Nitric oxide synthase inhibition blocks tolerance to the analgesic action of kappa-opiate receptor agonist in the rat
66. Evidence for the role of nitric oxide in kappa-opiate tolerance in mice
67. Kinetic properties of nitric oxide synthase in cerebral cortex and cerebellum of morphine tolerant mice
68. Visualization of time-dependent redistribution of ä-opioid receptors in neuronal cells during prolonged agonist exposure
69. Receptor-induced internalization of selective peptidic ì and ä opioid ligands
70. â-endorphin: Surface binding and internalization in thymoma cells
71. Down regulation of opiate receptor in neuroblastoma × glioma NG108-15 hybrid cells
72. U50, 488H-induced internalization of the human ê opioid receptor involves a â-arestin-and dynamin-dependent mechanism: Ê receptor internalization is not required for mitogen-activated protein kinase activation
73. Kappa opioid receptor endocytosis by dynorphin peptides
74. Mechanisms of agonist-induced down-regulation of the human ê-opioid receptor: Internalization is required for down regulation
75. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth
76. Quantitation of nitrate and nitrite in extracellular fluids
77. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction
78. Phagocytosis is regulated by Nitric Oxide in Murine Microglia
79. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluorosceins. Anal. Chem. 70 2446-2453 of the constitutive endothelial nitric oxide synthase gene in Alzheimer disease
80. Nitric oxide synthase structure and mechanism
81. The L-arginine-nitric oxide pathway